Cannon CP
Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Internet:
J Thromb Thrombolysis. 1995;2(3):205-218. doi: 10.1007/BF01062711.
Unstable angina and non--Q-wave myocardial infarction (MI) are at the center of the spectrum of myocardial ischemia, which ranges from stable angina to acute Q-wave MI. In addition to clinical evaluation, cardiac specific markers such as troponin T or I can assist in early diagnosis, triage, and risk stratification. Antithrombotic therapy with aspirin and heparin have been shown to improve the outcome of patients with acute ischemic syndromes. Thrombolytic therapy does not appear to be beneficial in these syndromes. Antiischemic therapy remains an important component of the overall therapy. A strategy of early coronary angiography and revascularization leads to a similar long-term outcome as compared with a more conservative strategy of revascularization for recurrent ischemia, but the early invasive strategy is more expeditious as a large number of conservatively treated patients have recurrent ischemia. At present, many new antithrombotic agents are under active investigation, with the hope that they will lead to further improvement in the clinical outcome of patients with acute ischemic syndromes.
不稳定型心绞痛和非Q波心肌梗死处于心肌缺血范围的中心位置,心肌缺血范围从稳定型心绞痛到急性Q波心肌梗死。除临床评估外,肌钙蛋白T或I等心脏特异性标志物有助于早期诊断、分诊和风险分层。已证明阿司匹林和肝素的抗栓治疗可改善急性缺血综合征患者的预后。溶栓治疗在这些综合征中似乎并无益处。抗缺血治疗仍然是整体治疗的重要组成部分。与针对复发性缺血的更保守的血运重建策略相比,早期冠状动脉造影和血运重建策略可带来相似的长期预后,但早期侵入性策略更为迅速,因为大量接受保守治疗的患者会出现复发性缺血。目前,许多新型抗栓药物正在积极研究中,希望它们能进一步改善急性缺血综合征患者的临床预后。